Systemic therapy for advanced gastric cancer: a clinical practice guideline.
about
Peripheral venous blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy.Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.Sinomenine sensitizes gastric cancer cells to 5-fluorouracil in vitro and in vivoEvaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models.Targeted therapies for lung cancer: clinical experience and novel agentsWhich is better for gastric cancer patients, perioperative or adjuvant chemotherapy: a meta-analysis.Intestinal metaplasia and the risk of gastric cancer in an immigrant asian population.Metastatic gastric cancer treatment: a little slow but worthy progress.Cost minimization analysis of capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong.Regenerating Family Member 4 (Reg4) Enhances 5-Fluorouracil Resistance of Gastric Cancer Through Activating MAPK/Erk/Bim Signaling Pathway.Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer.Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy.Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer.High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients.Enhanced RegIV expression predicts the intrinsic 5-fluorouracil (5-FU) resistance in advanced gastric cancer.
P2860
Q33714143-804D67BC-FDF6-43B5-9145-D5142502F69FQ34362184-6EEB0939-E724-42D8-B790-376712469131Q35048000-2542E80F-D223-45A6-B2E1-D1F1DC9F52BAQ35998729-564DA073-DEA9-41ED-A002-E96DDF3F4EB6Q36054970-F53B4D70-42A7-4792-8BA9-AFFD82CEDEB8Q36103180-9B1BC8BE-6806-493A-9E1B-334E573EF285Q37704530-21F4408D-309C-442C-A2F2-6609CF006106Q38075499-19EE4F16-377B-420C-84DF-3A38A4F555EBQ38918414-3A12F7B1-4F64-4933-9AFE-039F55DBE44AQ40101289-E4ED6163-3EF5-490D-91D4-970209EB5065Q45306704-EFB48283-9CAA-447D-BF5B-D6E02FD07FF0Q47144018-EF058392-02E4-4B53-9336-B7D2339D4F67Q50700149-29474709-13AC-48C1-89AA-78A28DA0FB6BQ53247758-EEC24EE3-294B-4AAA-8F20-02C258DE8789Q54290367-D64596D2-F717-4FA4-BA16-D7E055214619
P2860
Systemic therapy for advanced gastric cancer: a clinical practice guideline.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Systemic therapy for advanced gastric cancer: a clinical practice guideline.
@en
Systemic therapy for advanced gastric cancer: a clinical practice guideline.
@nl
type
label
Systemic therapy for advanced gastric cancer: a clinical practice guideline.
@en
Systemic therapy for advanced gastric cancer: a clinical practice guideline.
@nl
prefLabel
Systemic therapy for advanced gastric cancer: a clinical practice guideline.
@en
Systemic therapy for advanced gastric cancer: a clinical practice guideline.
@nl
P2093
P2860
P356
P1433
P1476
Systemic therapy for advanced gastric cancer: a clinical practice guideline.
@en
P2093
P2860
P304
P356
10.3747/CO.V18I4.737
P577
2011-08-01T00:00:00Z